MIOKARD INFARKTINING O‘TKIR BOSQICHIDA NATRIY–GLYUKOZA TRANSPORTYORI 2-TURI (SGLT2) INGIBITORLARINING KLINIK SAMARADORLIGI
Vol. 5 No. 12 (2026): Natural Sciences in the Modern World 6-7
Abstract
O‘tkir miokard infarkti (O‘MI) dunyo bo‘yicha yurak-qon tomir kasalliklari orasida o‘lim va nogironlikning asosiy sabablaridan biri bo‘lib qolmoqda. Zamonaviy reperfuziya usullari va medikamentoz davolashga qaramay, infarktdan keyingi yurak yetishmovchiligi, chap qorincha remodelatsiyasi hamda takroriy yurak-qon tomir asoratlari bemorlar prognozini yomonlashtirmoqda. So‘nggi yillarda natriy–glyukoza kotransportyori 2-turi (SGLT2) ingibitorlari yurak-qon tomir tizimiga ko‘rsatadigan kardioprotektiv ta'siri tufayli alohida ilmiy qiziqish uyg‘otmoqda. Ushbu preparatlarning o‘tkir miokard infarkti bilan kasallangan bemorlarda erta qo‘llanishi yurak funksiyasini saqlab qolish va yurak yetishmovchiligi rivojlanishining oldini olishdagi o‘rni hozirgi kunda dolzarb ilmiy masalalardan biri hisoblanadi.
References
McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3739.
Collet JP, Thiele H, Barbato E, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895–e1032.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). N Engl J Med. 2019;381:1995–2008.
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). N Engl J Med. 2020;383:1413–1424.
Readership
Downloads
Published
Issue
Section
How to Cite
